Heart Closure Devices Market Analysis

Heart Closure Devices Market Analysis

To get key market trends

  Download Free Sample

The heart closure devices market from left atrial appendage (LAA) closure devices segment is set to reach USD 2.9 billion by 2032, owing to the several advantages associated with these devices in the heart closure treatment procedures.  The primary advantage of LAAC devices is the significant reduction in the risk of stroke. LAAC devices provide an alternative to long-term anticoagulant therapy, such as warfarin or direct oral anticoagulants (DOACs). These medications are often associated with potential bleeding complications, drug interactions, and regular monitoring requirements. This is particularly advantageous for patients that are at high risk of bleeding due to various factors, such as advanced age, history of gastrointestinal bleeding, or concomitant use of other medications.
 

Moreover, LAAC devices can be implanted using minimally invasive techniques, such as percutaneous transcatheter approaches. This procedure is less invasive than open-heart surgery, resulting in shorter hospital stays, faster recovery times, and reduced post-operative complications.
 

The heart closure devices market from nitinol-based devices segment accounted for USD 1.1 billion revenue in 2022, due to the super elasticity and excellent biocompatibility associated with the nitinol-based heart closure devices. Nitinol allows heart closure devices to be compressed into a delivery catheter for minimally invasive procedures. Its super elasticity enables the device to withstand the dynamic forces and movements within the heart while maintaining its shape and function. In addition to nitinol, other materials such as polyester or polytetrafluoroethylene (PTFE) patches may also be used in conjunction with the closure devices to provide additional support and reinforce the closure. However, nitinol remains the primary material used in the design and construction of heart closure devices due to its unique properties and suitability for cardiovascular applications.
 

The heart closure devices market size from transcatheter delivery devices segment held over USD 1.4 billion in 2022. Transcatheter delivery is a less invasive approach compared to open-heart surgery. It involves making small incisions or punctures in the skin rather than a large incision in the chest. This leads to smaller scars, less pain, reduced risk of infection, and shorter recovery times. Transcatheter closure procedures generally result in a quicker recovery period compared to open-heart surgery.
 

Transcatheter procedures have observed to be associated with lower risks of complications such as the risks of infection, bleeding, and other surgical complications. Furthermore, transcatheter closure procedures are particularly beneficial for elderly patients and those with other health conditions. Transcatheter delivery allows these patients to undergo treatment with reduced risks and faster recovery times. As a result, several advantages associated with the transcatheter delivery in heart closure procedures will drive the segment revenue growth.
 

Heart closure devices market from hospitals segment is poised to exceed USD 3.2 billion by 2032. The soaring use of novel heart closure devices in hospital settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities. The availability of a broad spectrum of devices for performing these procedures with proven accuracy is set to drive product preference in hospitals. Growing admissions with cardiac ailments and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment growth positively. Furthermore, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals. As a result, accessibility to an effective diagnosis coupled with the rising prevalence of cardiovascular diseases and associated conditions will boost the patient visits to hospitals, thereby propelling the segment revenue growth.
 

U.S. heart closure devices market is anticipated to cross USD 2.7 billion by 2032, owing to several factors such as the presence of major companies, an upsurge in the demand for heart closure procedures, rise in the prevalence of cardiovascular conditions, and growing number of hospital admissions across the country among others. As per the American Heart Association data 2022, the age adjusted death-rate attributable to cardiovascular diseases was 224.4 per 100,000 population. Additionally, in 2020, coronary heart disease (41.2%) was the leading cause of deaths followed by stroke (17.3%), heart failure (9.2%), etc. in the U.S.
 

These adverse events are anticipated to upsurge the adoption rate of cardiovascular devices for better CVD management. Moreover, the U.S. is one of the leading nations in terms of heart care initiatives and the government has employed several guidelines to bolster heart comprising the Million Hearts initiative. These initiatives adopted by the public as well as private organizations would further promote the product demand to maintain precise heart health and physical & mental wellbeing among cardiac patients.